Methods of preventing or treating cardiovascular, cerebrovascular and thrombotic disorders with tumor necrosis factor antagonists

Abstract

A method of treating or preventing a cardiovascular and/or a cerebrovascular disorder in an individual is disclosed. Also disclosed is a method for treating and/or preventing a thrombotic disorder in an individual. Further disclosed is a method of decreasing plasma fibrinogen in an individual.

1 - 50 . (canceled) 
     
     
         51 . A method of treating a thrombotic disorder in an individual in need thereof comprising administering a therapeutically effective amount of an anti-human tumor necrosis factor-α monoclonal antibody or antigen-binding fragment thereof to the individual, wherein the thrombotic disorder is selected from the group consisting of: a thromboembolic disorder, an ischemic event, stroke, acute myocardial infarction, deep vein thrombosis and thrombophlebitis. 
     
     
         52 . The method of  claim 51 , wherein the monoclonal antibody is selected from the group consisting of a humanized antibody or antigen-binding fragment thereof and a resurfaced antibody or antigen-binding fragment thereof. 
     
     
         53 . The method of  claim 51 , wherein the monoclonal antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO: 2) or about 59-80 (SEQ ID NO: 1) of human tumor necrosis factor-α. 
     
     
         54 . The method of  claim 51 , wherein the monoclonal antibody is a chimeric antibody, said chimeric antibody comprising (a) a non-human variable region specific for tumor necrosis factor or an antigen-binding portion thereof and (b) a human constant region. 
     
     
         55 . The method of  claim 54 , wherein the chimeric antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO: 2) or about 59-80 (SEQ ID NO: 1) of human tumor necrosis factor-α. 
     
     
         56 . The method of  claim 54 , wherein the chimeric antibody is monoclonal antibody cA2. 
     
     
         57 . The method of  claim 54 , wherein the chimeric antibody competitively inhibits binding of tumor necrosis factor-α to monoclonal antibody cA2. 
     
     
         58 . The method of  claim 51 , wherein the thrombotic disorder is acute myocardial infarction, deep vein thrombosis or thrombophlebitis.